Elisabeth Schültke1, Sam Bayat2, Stefan Bartzsch3, Elke Bräuer-Krisch4, Valentin Djonov5, Stefan Fiedler6, Cristian Fernandez-Palomo5, Felix Jaekel7, Paolo Pellicioli4, Verdiana Trappetti5, Guido Hildebrandt7. 1. Department of Radiooncology, Rostock University Medical Center, Rostock, Germany. Electronic address: elisabeth.schueltke@med.uni-rostock.de. 2. STROBE Laboratory, Grenoble Alps University, Inserm UA, Grenoble, France; Grenoble Alps University Hospital, Grenoble, France. 3. Department of Radiooncology, Technical University Munich, Munich, Germany; Institute for Innovative Radiotherapy, Helmholtz-Zentrum Munich (HMGU), Munich Germany. 4. European Synchrotron Radiation Facility, ID17 Biomedical beamline, Grenoble, France. 5. Institute of Anatomy, University of Bern, Bern, Switzerland. 6. European Molecular Laboratory (EMBL), Hamburg, Germany. 7. Department of Radiooncology, Rostock University Medical Center, Rostock, Germany.
Abstract
PURPOSE: Radiation therapy is an important treatment component for patients with lung cancer. However, the survival time gained with clinical radiation therapy techniques is relatively short. Data from preclinical experiments suggest that synchrotron microbeam radiation therapy could be much better suited to control malignant brain tumors than current clinical concepts of radiation therapy. Even at peak doses of several hundred gray, the extent of functional deficits is low. METHODS AND MATERIALS: We have developed the first mouse model to study the effects of microbeam irradiation in lung tissue. RESULTS: Up to peak doses of 400 Gy, no acute adverse effects were seen. CONCLUSION: This model is well suited to explore the potential of microbeam radiation therapy in the treatment of lung cancer and the response of normal lung tissue and organs at risk.
PURPOSE: Radiation therapy is an important treatment component for patients with lung cancer. However, the survival time gained with clinical radiation therapy techniques is relatively short. Data from preclinical experiments suggest that synchrotron microbeam radiation therapy could be much better suited to control malignant brain tumors than current clinical concepts of radiation therapy. Even at peak doses of several hundred gray, the extent of functional deficits is low. METHODS AND MATERIALS: We have developed the first mouse model to study the effects of microbeam irradiation in lung tissue. RESULTS: Up to peak doses of 400 Gy, no acute adverse effects were seen. CONCLUSION: This model is well suited to explore the potential of microbeam radiation therapy in the treatment of lung cancer and the response of normal lung tissue and organs at risk.
Authors: Kim Melanie Kraus; Johanna Winter; Yating Zhang; Mabroor Ahmed; Stephanie Elisabeth Combs; Jan Jakob Wilkens; Stefan Bartzsch Journal: Cancers (Basel) Date: 2022-01-28 Impact factor: 6.639
Authors: Elisabeth Schültke; Michael Lerch; Timo Kirschstein; Falko Lange; Katrin Porath; Stefan Fiedler; Jeremy Davis; Jason Paino; Elette Engels; Micah Barnes; Mitzi Klein; Christopher Hall; Daniel Häusermann; Guido Hildebrandt Journal: J Synchrotron Radiat Date: 2022-05-18 Impact factor: 2.557
Authors: Munir A Al-Zeer; Franziska Prehn; Stefan Fiedler; Ulrich Lienert; Michael Krisch; Johanna Berg; Jens Kurreck; Guido Hildebrandt; Elisabeth Schültke Journal: Int J Mol Sci Date: 2022-09-01 Impact factor: 6.208